Why the study?
Does spironolactone improve LV diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy?
Does spironolactone improve LV diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy?
Spironolactone improves diastolic function and reduces myocardial fibrosis in mildly symptomatic DCM patients, specifically those with baseline collagen accumulation.
Spironolactone may benefit fibrotic DCM; hypothesis-generating pilot data requiring larger RCTs before practice change.
Spironolactone ameliorated LV diastolic dysfunction and reduced chamber stiffness in association with regression of myocardial fibrosis in mildly symptomatic patients with DCM. These effects appeared limited, however, to patients with increased myocardial collagen accumulation.
No takes yet. Share an insight, caveat, or question.
Izawa et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: